P72-5 Is rapid antigen detection test suitable as community screening for SARS-CoV-2?

Abstract

Vulnerable cancer patients are at increased risk of severe COVID-19. Early testing and detection is vital to prevent transmission of SARS-CoV-2 to cancer patients and the community. Although rRT-PCR is the gold standard to detect SARS-CoV-2, lateral flow devices (LFDs) for rapid antigen testing are set to become a keystone of SARS-CoV-2 mass community testing because of its convenience and high sensitivity. There is limited information on how well they identify infectious cases. Understanding their performance and limitations is, therefore, essential for successful strategy implementation.